Ways to Successful Strategies in Drug Research and Development

Ways to Successful Strategies in Drug Research and Development

Volumn , Issue , 2008, Pages 1-265

  Sedlacek, H Harald ^a   Sapienza, Alice M ^b,c   Eid, Volker ^d  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b SIMMONS COLLEGE   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF BAMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MANAGERS; PROJECT MANAGEMENT;

DRUG RESEARCH; EVALUATION AND SELECTIONS; KEY TOPICS; PHARMACEUTICAL INDUSTRY; POLITICAL PARAMETERS; SCIENTIFIC KNOWLEDGE; TECHNOLOGY STRATEGIES;

RISK ASSESSMENT;

EID: 84950115244     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527615018     Document Type: Book

References (212)

1. Ach, N.: Analyse des Willens. In: E. Abderhalden (ed.), Handbuch der biologischen Arbeitsmethoden, Urban & Schwarzenberg, Berlin, 1935.
2. Albach, H.: Innovation: Kooperation von Unternehmen und Staat im globalen Wettbewerb. In: Pharmastandort Deutschland-Eine Standortbestimmung. Verband Forschender Arzneimittelhersteller 1994.
3. Amabile, T.M.: Within you, without you: The social psychology of creativity, in: Theories of Creativity, Runco, M.A. and Albert, R.A. (eds.), Sage Publications, Newbury Park, CA, 1990.
4. Ansoff, H.I.: Implanting strategic management. Prentice-Hall Int., Englwood Cliffs, New Jersey, 1984.
5. Anthony, R., Welsch and Reece: Fundamentals of Management Accounting; 4th Edition, 451-472,1979.
6. Aquin von, T.: Summa theologica 11/30, cited according to G.M. Teutsch, 1984.
7. Archer, L.; Mikkelsen, M.; Schroten, E.; Hottois, G.; Quintana-Tria, O.; McLaren, A.; Rodota, S. and Mieth, D.: The ethical aspects of gene therapy. Press dossier relative to the opinion from the Group of Advisers on Ethical Implications of Biotechnology (GAEIB) 4: 1994.
8. Argyris, C: Leadership, learning, and changing the status quo. Organizational Dynamics 4: 29-3,1976.
9. Assisi von, F.: Lexikon der Namen und Heiligen, Tyrolin Verlag, Innsbruck, 1982.
10. Atkinson, J.W.: An introduction to motivation. Princeton, N.J.: van Nostrand, 1964.
11. Avery, CM. and Smilor, R.W.: Research consortia: The microelectronics and computer technology corporation, in: Technology Transfer: A Communication Perspective, Williams, F. and Gibson, D.V. (eds.), Sage Publications Inc., Newbury Park, CA, 1990.
12. Bacon, F.: Nova Atlantis, cited according to Kinder Literaturlexikon, Deutscher Taschenbuch Verlag, 1974.
13. Barrai, P.E.: 15 ans de résultats de la recherche pharmaceutique dans le monde (1975-1989), Rhône-Poulenc Santé, Paris, 1990.
14. Barrai, P.E.: 18 ans de résultats de la rechere pharmaceutique dans le monde (1975-1989), presentation at CREDES & CES European Conference "From Economic Analysis to Health Policies", Paris 18th December 1992.
15. Bass, B.M.: Leadership, psychology and organizational behaviour. New York: Harper, 1960.
16. Bass, B.M.: Leadership and performance beyond expectations. New York: Free Press, 1985.
17. Beauchampt, T.; Childress, J.F.: Principles of bioethics. Oxford University Press, New York, 1983.
18. Berger, P.L. and Luckmann, T.: The social construction of reality. Doubleday, Gardenlity, New York, 1966.
19. Bernard, J.; Kajikawa, K. and Fujiki, N.: Human dignity and medicine. Elsevier Science, Inc., New York 1988.
20. Bernhard, L.A. and Walsh, M.: Leadership: the key to the professionalization of nursing. 1990, cited according to Lee, The Kansas Nurse, January 1992.
21. Bingham, W.V.: Leadership, in: Metealf, H.C. (ed.), The Psychological Foundations of Management. New York, Shaw, 1927.
22. Black, Sir James: Drug Research, unpublished paper, 1986.
23. Böckle, F.: Das Tier als Gabe und Aufgabe. Von der kreatürlichen Verantwortung des Menschen. In: Tierschutz: Testfall unserer Menschlichkeit (Händel, U.M., ed.), Fischer Taschenbuch Verlag, Frankfurt, 1984.
24. Böckle, F.: Leben bleibt immer lebensgefährlich. Lecture, St. Goar, 28. November 1990.
25. Bolognese, J.A.: A Monte Carlo comparison of three up-and-down designs for dose ranging. Controlled Clin. Trials. 4:187-196,1983.
26. Brown, T.J.: Heath economics-added value or abscure outcome? Scrip Magazine 12,1994.
27. Bundesverband der Pharmazeutischen Industrie e.V., Pharma Daten 1993.
28. Burns, J.M.: Leadership. New York: Harper and Row, 1978.
29. Byrne, A.: The miracle company. Business Week, 84-90, October 19,1987.
30. Campbell, P. and Dee Mahan, J.D.: Biopharmaceutical reimbursement planning: assessing payer risks to design a competitive strategy. Decision Resources, 36/1-36/8, May 1992.
31. Carlyle, T.: Heroes and hero worship. Boston: Adams, 1841.
32. Cattell, R.B.: The scientific analysis of personality. Baltimore: Penguin, 1965.
33. Coates, G.: Motivation theories' lacklustre performance: identity at work as explanation for expended effort. Educational Training Technol. Intern. 31:26-30,1994.
34. Collins, J.M., Grieshaber, C.K. and Chabner, B.A.: Pharmacologically guided phase I clinical trials based upon preclinical drug development. J. Natl. Cancer Inst. 82: 1321-1326,1990.
35. Cropanzano, R.; James, K. and Citera, M.: A goal hierarchy model of personality, motivation, and leadership. Res. Organizational Behavior 15: 267-322,1992.
36. Dalen, J.E. and Hirsh, J.: American College of Chest Physicians and the National Heart, Lung and Blood Institute. National Conference on Antithrombotic Therapy. Arch. Intern. Med. 146: 462-172,1986.
37. D'Arcy, P.F. and Harron, D.W.G.: Proceedings of the first International Conference on Harmonisation, Brussels 1991. Belfast: The Queen's University of Belfast, cited according to Scrip Reports: Ethical and Legal issues in the Pharmaceutical Industry, January 1994.
38. Davison, R.: The future for R&D investment-law of diminishing returns. Scrip Magazine, July/August 1994.
39. DiMasi, J.A., Hansen, R.W., Grabowski, H.G. and Lasagna, L.: Cost of innovation in the pharmaceutical industry. J. Health Economics 10:107-192,1991.
40. Drews, J.: The impact of cost containment on pharmaceutical research and development. Centre for Medicines Research, 10th CMR Annual Lecture, June 1995.
41. Drucker, R.R.: The practice of management. London. William Heinemann Ltd. 194, 1955.
42. Düker, H.: Untersuchungen über die Ausbildung des Wollens. Bern: Huber, 1975.
43. Eden, D.: Self-fulfilling prophecy as a management tool: Harnessing Pygmalion. Academy of Management Rev. 9: 64-73,1984.
44. Eid, V.: Grundsätze medizinischer Ethik aus theologisch-ethischer Sicht, in: Reiter, J. und Theile, U. (eds.), Genetik und Moral, Beiträge zu einer Ethik des Ungeborenen, Grünewald, Mainz 162-170,1985.
45. Emanuel, E.J.: The ends of human life: medical ethics in a liberal polity. Harvard Univ. Press, Cambridge, 1991.
46. Engelhardt, H.T.: The foundations of bioethics. Oxford University Press, New York, 1986.
47. Eser, A.; Lutterotti von, M. and Sporken, P.: Lexikon Medizin Ethik Recht, Herder, Freiburg, 1989.
48. Evans, M.G.: The effects of supervisory behaviour on the path-goal relationship. Organizational Behaviour and Human Performance 5: 277-298,1970.
49. Evans, M.G.: Organizational behaviour: the central role of motivation. J. Management 12: 203-222,1986.
50. Farrington, D.P.: Motivations for conduct disorder and delinquency. Developm. Psychopath. 5: 225-241,1993.
51. Fiedler, F.E.: A contingency model of leadership effectiveness, in: Berkowith, L. (ed.), Advances in experimental social psychology. New York: Academic Press, 1964.
52. Fox, R.M.: Situations creating ethical stress. Med. J. Aust. 1:162-163,1981.
53. Freedman, B.: Cohort-specific consent: an honest approach to phase I clinical cancer studies. IRB 12: 5-7,1990.
54. Freedman, B.; Fuks, A. and Weijer, C: Demarcating research and treatment: a systemic approach for the analysis of the ethics of clinical research. Clin. Res. 40: 653-660,1992.
55. French, J.R.P.: A formal theory of social power. Psychol. Rev. 63:181-194,1956.
56. Freud, S.: Drei Abhandlungen zur Sexualtheorie. In: Gesammelte Werke, London: Imago, 1942.
57. Freud, S.: Triebe und Triebschicksale. In: Gesammelte Werke, London: Imago, 1915.
58. Galbraith, J.R.: Organization Design: An Information Processing View. In: Organizational Planning: Cases and Concepts, J. Lorsch and P. Lawrence (eds.), Irwin-Dorsey Ltd., Georgetown, OH, 1972.
59. Galbraith, J.: Designing complex organizations. Addison-Wesley, Rading, M.A., 1973.
60. Gardner, D.G. and Cummings, L.L.: Activation theory and job design: review and reconceptualization, in: Staw, B.M. and Cummings, L.L. (eds.), Research in organizational behavior 10: 81-121, Greenwich, CT: JAI Press, 1988.
61. Gassen, H.G.; König, B. and Bangsow, T.: Pharmaforschung im Zeichen der Biotechnologie. Pharm. Ind. 56: 667,1994.
62. Genesis 1-50: Die Bibel, Einheitsübersetzung, Paul Pattoch Verlag, Aschaffenburg, 1980.
63. Gerson, G.: The threat of the efficient generic market. Scrip Magazine 11: 6,1994.
64. Golden, K.A.: Individual and organisational culture: strategies for action in highly ordered contexts. J. Management Studies 29:1-21,1992.
65. Good, B.: Industry and the Environment: a strategic overview. CEST Report 1991. London: CEST cited according to Scrip Reports: Ethical and Legal Issues in the Pharmaceutical Industry, January 1994.
66. Graen, G. and Cashman, J.: A role-making model of leadership in formal organizations: a developmental approach, in: Hunt, J.G. and Larson, L.L. (eds.), Leadership Frontiers. Kent: Kent State University Press, 143-165,1975.
67. Grieshaber, C.K. and Marsoni, S.: Relation of preclinical toxicology to findings in early clinical trials. Cancer Treat. Rep. 70: 65-72,1986.
68. Gunson, B. and Goodman, H.: How to handle high cost products. Pharmaceutical Marketing 5: 23-24,1993.
69. Haimann, T.: Supervisory management for health care institutions St. Louis, MO. The Catholic Hospital Association 1973.
70. Halliday, R., Walker, S.R. and Lumley, C.E.: R&D philosophy and management in the world's leading pharmaceutical companies. J. Pharm. Med. 2:139-154,1992.
71. Hansen, R.W.: The pharmaceutical development process: Estimates of current development costs and times and the effects of regulatory changes, in: Issues in pharmaceutical economics, Chien, R.L. (ed.), Lexington Books, Lexington, MA, 151-187,1979.
72. Harrington, D.M.: The ecology of human creativity. In: Theories of Creativity, Runco, M.A. and Albert, R.A (eds.), Sage Publications, 2 Newbury Park, CA, 1990.
73. Harvey C: Approval systems and the single European market. Scrip Magazine, 12, 1993.
74. Heckhausen, H.: Hoffnung und Furcht in der Leistungsmotivation. Meisenheim: Hain, 1963.
75. Hersberg, F., Mausner, B. and Snyderman, B.: The motivation to work. John Wiley and Sons, Inc. New York, 1959.
76. Hohlneicher, G.: Schlußbetrachtungen. In: Leben ohne Risiko? Ein Beitrag zur umweltorientierten Risikoabschätzung und -akzeptanz (Ders. und E. Raschke, eds.), Köln, 1989.
77. Holton, G.: Thematic origins of scientific thought, Harvard University Press, Cambridge, MA, 354,1973.
78. Holton, G.; The scientific imagination. Cambridge University Press, Cambridge, England, 281,1978.
79. Hone, J.: Healthcare-a question of economy, efficiency and ethics. Scrip Magazine, December 1993.
80. Hone, J.: Ethics committees and the question of judgement. Scrip Magazine, September 1994.
81. Hook, S.: The hero in history. New York: John Day, 1943.
82. House, R.J.: A1976 charismatic theory of leadership, in: Hunt, J.G. and Larson, L.L. (eds.), Leadership: The Cutting Edge. Carbondale: Souhter Illinois University Press, 1977.
83. Hull, C.L.: A behavior system: An introduction to behavior theory concerning the individual organism. New Haven: Yale University Press, 1952.
84. Hungerer D. and Cambillard, P.: Personal communication. Behringwerke 1994.
85. Jacobs, T.O.: Leadership and exchange in formal organizations. Alexandria: Human Resources Research Organization, 1970.
86. James, W.: The principles of psychology. New York: Holt, 1890.
87. Jonas, H.: Das Prinzip Verantwortung, Versuch einer Ethik für die technologische Zivilisation, S. 172, Frankfurt 1979.
88. Jonas, H.: Das Prinzip der Verantwortung. Insel Verlag, Frankfurt 1987.
89. Jonas, H.: Technik, Ethik und biogenetische Kunst. Betrachtungen zur neuen Schöpferrolle des Menschen. In: Ethik und Gentechnologie (Jonas, H., Vogel, F., Catenhusen, W.-M., Ev. Kirche Deutschland, Reiter, J., eds.), GG + F, 1988.
90. Jorgensen, S., Jensen, I and Edwards, M.: Surviving as a niche player in the pharmaceutical industry. Drug Developm. Res. 30: 112-120,1993.
91. Kant, I.: In: Pfeiffer, J. (ed.). Kant Brevier 3rd Edition. Marion von Schröder Verlag, Hamburg, 1974.
92. Kant, I.: In: G. Stenzel, (ed.). Die Grundlagen des kritischen Denkens. Sigbert Mohn Verlag, Berlin 1955.
93. Kanter, R.: Supporting innovation and venture development in established companies. J. Business Venturing 1: 47-60,1985.
94. Keisling, K.R.: Project management in the Pharm. Industry, in: Clin. Res. Practices & Drug Reg. Affaires 1: 27-34,1983.
95. Kerr, S. and Jermier, J.M.: Substitutes for leadership: their meaning and measurement. Organizational behaviour and human performance 18: 329-345,1978.
96. Khorramshahgol, R. and Steiner, H.M.: Resource analysis in project evaluation: a multicriteria approach. J. Opl. Res. Soc. 39: 795-803, 1988.
97. Khoury, T.: Buddhismus. In: Die fünf großen Weltreligionen. E. Brunner-Traut, Herder-Verlag, Freiburg, 1984.
98. Kidd, G. and Dvorak J.: Does the first to reach the market always win? Bio/Technol. 13: 642,1995.
99. King, A.S.: Evolution of leadership theory. Vicapla 15: 43,1990.
100. Kuhl, J.: Motivation, Konflikt und Handlungskontrolle. Berlin: Springer, 1983.
101. Kusyszyn, I.: Existence, effectance, esteem: from gambling to a new theory of human motivation. Int. J. Addict. 25:159-177,1990.
102. Lee, C.A.B.: Classic leadership theories and roles. The Kansas Nurse, January 1992.
103. Leonard-Barton, D.: The organizational setting of technology transfer, in: Technology Transfer: A Communication Perspective, Williams, F. and Gibson, D.V. (eds.), Sage Publications Inc., Newbury Park, CA, 1990.
104. Levine, R.J.: Ethics and regulation of clinical research. Williams and Wilkins, Baltimore 1986.
105. Lewin, K.: Untersuchungen zur Handlungs- und Affektpsychologie. II. Vorsatz, Wille und Bedürfnis. Psychologische Forschung 7: 330-385,1926.
106. Lieberman, M.B. and Montgomery, D.B.: First-mover advantages. Strategie Management Journal 9: 41-58,1988.
107. Locke, E.A. and Latham, G.P.: A theory of goal setting and task performance. Englewood Cliffs, NJ: Prentice-Hall, 1990.
108. Lorenz, K.: Über die Bildung des Instinktbegriffes. Naturwissenschaften 25: 289-300, 307-318 and 325-331,1937.
109. Lorz, A.: Die Entwicklung des deutschen Tierschutzrechts. In: Tierschutz: Testfall unserer Menschlichkeit, U.M. Händel (ed.), Fischer Taschenbuch Verlag, Frankfurt, 1984.
110. Lynoel, N., Sandlund, M., Dahlquist, G. and Jacobsen, L.: Informed consent: study of quality of information given to participants in a clinical trial. BMJ 303: 610-613, 1991.
111. Maclnnes, R.: Fewer NCEs reach the market in the 1990s. CMR News 13, 1995.
112. Maclean, A.: The elimination of morality. Reflections on utilitarianism. Routledge, London 1993.
113. Maddox, J.: How could EU research be improved? Nature 377: 571-572,1995.
114. Manz, C.C. and Sims, H.P.: Leading workers to lead themselves: the external leadership of self-managing work teams. Administrative Science Quarterly 32: 106-128,1987.
115. Marcel, T.: A guide to building successful biotech alliances. Scrip Magazine 2,1994.
116. Markl, H.: Forschung, Innovation und Wettbewerb. Strategie für die Zukunft. In: Pharmastandort Deutschland-eine Standortbestimmung (Rexrodt, G., Markl, H., Albach, H und Wenninger, W., eds.), Verband Forschender Arzneimittelhersteller e.V., 1994.
117. Markman, M.: The ethical dilemma of phase I clinical trials. Ca. Cancer J. Clin. 36: 367-269,1986.
118. Maslow, A.H.: Motivation and personality. New York: Harper, 1954.
119. Maurer, P.R.: Japan's response to rising healthcare costs. Scrip Magazine 12,1994.
120. McClelland, D.C., Atkinson, J.W., Clark, R.A. and Lowell, E.L.: The achievement motive. New York: Appleton-Century-Crofts, 1953.
121. McClelland, D.: Motives, personality, and society. Praeger, New York, New York, 1984.
122. McDaugall, W.: An introduction to social psychology. London: Methuen (dt.: Grundlagen einer Sozialpsychologie, Jena: Fischer, 1928), 1908.
123. McGregor, D.: The human side of enterprise. New York: McGraw-Hill and McGregor, D. Leadership and motivation. Boston: Massachusetts Institute of Technology Press, 1966.
124. Meyer-Abich, K.M.: Das Recht der Tiere, Grundlagen für ein neues Verhältnis zur natürlichen Mitwelt. In: Tierschutz: Testfall unsererMenschlichkeit (Händel, U.M., ed.), Fischer Taschenbuch Verlag, Frankfurt, 1984.
125. Miller, H.I.: Drug approvals. Nature 356: 189,1992.
126. Moorhead, G. and Griffin, R.W.: Organizational behavior. Houghton Mifflin Company, Boston, MA, 1995.
127. Mowrer, O.H.: Learning theory and behavior, New York: Wiley, 1960.
128. Murray, H.A.: Explorations in personality. New York, Oxford, 1938.
129. O'Quigley, J., Pepe, M. and Fisher, L.: Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 46: 33-48,1990.
130. Owens, J.: The uses of leadership theory, in: Hicks, H. and Powell, J.D. (eds.), Management, organizations and human resources: selected readings. New York: McGraw-Hill, 226-234,1976.
131. Pellegrino, E.D. and Thomasma, D.C.: For the patient's good: the restauration of beneficence in health care. Oxford, Univ. Press, New York, 1988.
132. Penta, J.S., Rosner, G.L. and Trump, D.L.: Choice of starting dose and escalation for phase I studies of antitumor agents. Cancer Chemother. Pharmacol. 31: 247-250, 1992.
133. Pergamon von, Galenos, cited according to H.G. Wolters, 1982.
134. Pervin, L.A.: Goal concepts in personality and social psychology: an historical perspective, in: Pervin, L.A. (ed.), Goal concepts in personality and social psychology, 1-17, Hillsdale, NJ: Erlbaum, 1989.
135. Peters, T.J. and Waterman, R.H.: In search of excellence: lessons from America's best-run companies. New York: Warner Books, 1982.
136. Pfeffer, J.: The ambiguity of leadership. Academy of Management Rev. 2: 104-112, 1977.
137. Plutarch, cited according to G.M. Teutsch, 1984.
138. Porter, M.: Competitive strategy, New York The Free Press, p. 45,1980.
139. Porter, M.E.: How competitive forces shape strategy. Harvard Business Review, March 1979.
140. Porter, M.E.: From competitive advantage to corporate strategy. Harvard Business Review, May-June 1987.
141. Powell, T.E.: A review of recent development in project evaluation. Chem. Engin. 92:187,1985.
142. Prange, R.: Personal communication, Behringwerke, Marketing and Sales, 1994.
143. Pulazzini, A.: Achieving the right communication mix. Scrip Magazine, May 1994.
144. Pythagoras, cited according to G.M. Teutsch, 1984.
145. Quinn, J.B.: Managing innovation: controlled chaos. Harvard Business Reviews, May/June 1985.
146. Ratain, M.J., Mick, R., Schilsky, R.L. and Siegler, M.: Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J. Natl. Cancer Inst. 85:1637,1993.
147. Redwood, H.: Price regulation and pharmaceutical research. The limits of co-existence. Oldwicks Press Ltd., England, 1993.
148. Remer, D.S.; Stokdyk, S.B. and Vandriel, M.: Survey of project evaluation techniques currently used in industry. Int. J. Product. Econ. 32:103-115,1993.
149. Rotter, J.B.: Social learning and clinical psychology. New York: Prentice-Hall, 1954.
150. Roussel, P.A.; Saad, K.N. and Erickson, T.J.: Third Generation R&D. Managing the Link to Corporate Strategy. Harvard Business School Press, 1991.
151. Rumelhart, D.E., Smolesky, P., McClelland, J.L. and Hinton, G.E.: Schemata and sequential thought processes in PDP models, in: Parallel Distributed Processing, McClelland, J.L. and Rumelhart, D.E. et al. (eds.), The MIT Press, Cambridge, MA, 1986.
152. Sade, R.M.: Issues of social policy and ethics in gene technology. Meth. Find. Exp. Clin. Pharmacol. 16: 477-489,1994.
153. Sapienza, A.M.: Believing is seeing. In: R.H. Kilmann et al. (eds.), Gaining Control of the Corporate Culture, Jossey-Bass, San Francisco, CA, 1985.
154. Sapienza, A.M.: The paradox of a successful drug discovery: the story of Tagament. Harvard School of Public Health case study, Boston, MA, 1987.
155. Sapienza, A.M.: Preparing for globalization: Takeda Chemical Industries, Central Research Division, Harvard School of Public Health Case Study, Boston, MA, 1989.
156. Sapienza, A.M.: Assessing the R&D capability of the Japanese pharmaceutical industry. R&D Management 23: January 1993.
157. Sapienza, A.M. and Innami, I.: Managing the R-to-D handoffs of breakthrough innovations in the pharmaceutical industry, presented at the Project Management Institute Annual Meeting, Pittsburgh, September 1993.
158. Sapienza, A.M.: Managing scientists. John Wiley & Sons, New York, 1995.
159. Schein, E.: How culture forms, develops, and changes. In: R.H. Kilmann et al. (eds.), Gaining Control of the Corporate Culture, Jossey-Bass, San Francisco, CA, 1985.
160. Schenk, C: Leadership. Infantry J. 33:111-122,1928.
161. Schneider, H.G.: Personal information, Hoechst AG, Pharmaceutical Division, Market Research, 1995.
162. Schopenhauer, A.: Gesammelte Werke. Hanser, München, 1977.
163. Schweizer, A.: Die Lehre der Ehrfurcht vor dem Leben. 2. Aufl., Union Verlag, Berlin, 1963.
164. Scrip No. 1962, PJB Publications Ltd.:Top 25 products in 1993. September 1994.
165. Scrip No. 2045, PJB Publications Ltd.: UK NCE assessment in 56 days. July 1995.
166. Scrip No. 2040, PJB Publications Ltd.: PhRMA's FDA reform plan. July 1995.
167. Scrip No. 2028, PJB Publications Ltd.: Disease management-a tool for industry and MCOs. May 1995.
168. Scrip No. 2026, PJB Publications Ltd.: World pharma market to 1999. May 1995.
169. Scrip Magazine: Merck and Glaxo storm ahead. January 1995.
170. Scrip Magazine: Research targets in 1994. January 1995.
171. Scrip Magazine: Therapeutic advances in the NCEs of 1994. January 1995.
172. Scrip Reports: Ethical and legal issues in the pharmaceutical industry. January 1994.
173. Sedlacek, H.H.: Tierschutz und Tumorforschung. Ein Beitrag zur aktuellen Diskussion. Pharma Dialog Nr. 92,1986.
174. Seligman, M.E.P.: Helplessness: On depression, development, and death. San Francisco: Freeman, 1975.
175. Shaffer, M.: Drugs approved in 1991. FDA Talk Paper, Food and Drug Administration, U.S. Department of Health and Human Services, January 5th, 1992.
176. Shamir, B.: Calculations, values and identities: the sources of collective motivation. Human Relations 43: 313-332,1990.
177. Shamir, B.: The charismatic relationship: alternative explanations and predictions. Leadership Quarterly 2: 81-104,1991.
178. Sims, H.P.: The leader as a manager of reinforcement contingencies: an empirical example and a model, in: Hunt, J.G. and Larson, L.L. (eds.), Leadership: The Cutting Edge. Carbondale: Southern Illinois University Press, 1977.
179. Sounder, W.E.: Stimulating and Managing Ideas. Res. & Techn. Managern. 30: 13, 1987.
180. Spadaro, D.: Project evaluation made simple. Datamation 31: 121,1985.
181. Spaemann, R.: Tierschutz und Menschenwürde. In: Tierschutz: Testfall unserer Menschlichkeit, U.M. Händel (ed.), Fischer Taschenbuch Verlag, Frankfurt, 1984.
182. Special Report: Top 100 drugs. Pharma Business p. 12,1995.
183. Spence, K.W.: Behavior theory and conditioning. New Haven: Yale University Press, 1956.
184. Spitzy, K.H.; Hitzenberger, G. and Lau, I.: Der Versuch am Menschen in der Wiener Medizinischen Schule in Selbstdarstellungen. Wilhelm Maudrich, Wien 1984.
185. Steiner, G.A.: Strategie Planning. New York, NY: The Free Press, A Division of Macmillan Publishing Co., Inc., 16-23,1979.
186. Stewart, A.J.: Motivation and society, Jossey-Bass, San Francisco, CA, 1982.
187. Stewart, A.J. and Chester, N.L.: Sex differences in human social motives. In: Stewart, A.J. (ed.), Motivation and Society, Jossey-Bass, San Francisco 1982.
188. Stogdill, R.M.: Individual behaviour and group achievement. New York: Oxford University Press, 1959.
189. Struck, M.M.: Biopharmaceutical R&D success rates and development times. A new analysis provides benchmarks for the future. Bio/Technol. 12: 674,1994.
190. Stucki, J.C.: A goal-oriented pharmaceutical research & development organization: an eleven year experience, in: R&D Management 10: 3,1980.
191. Sullivan, J.J.: Self theories and employee motivation. J. Management 2: 345-363, 1989.
192. Terpstra, D.E.: Theories of motivation-borrowing the best. Personnel J., 376-379, 1979.
193. The Boston Consulting Group: The changing environment for US pharmaceuticals. April 1993.
194. The Rules Governing Medicinal Products in the European Community, vol. III, addendum 3. Guidelines on the quality, safety, and efficacy of medicinal products for human use. Environemntal risk assessment for human medicinal products containing or consisting of GMOs. January 1995.
195. Tölle-Kastenbein, R.: Das Genfer Arztgelöbnis und der Hippokratische Eid. Duris Verlag, Bochum, 1985
196. Tolman, E.C.: Purposive behavior in animals and men. New York: Appleton, 1932.
197. Trist, E.L. and Bamforth, K.W.: Some social and psychological consequences of the Longwall method of goal setting. Human Relations 4: 3-38,1951.
198. United States General Accounting Office: Prescription drugs: Spending controls in four European countries. Washington, DC, 1994.
199. United States Office of Technology Assessment: Pharmaceutical R&D: Costs, risks and rewards. Washington, DC, February 1993.
200. Vroom, V.H.: Work and motivation. Wiley, New York, 1964.
201. Vroom, V.H. and Jago, A.G.: On the validity of the Vroom-Yetton model. J. Applied Psychology 63:151-162,1978.
202. Watts, G.: Key issues for the future. Scrip Magazine 11: 36, 1994.
203. Weiner, B.: An attributional theory of achievement motivation and emotion. Psychological Rev. 92: 548-573,1985.
204. Wenninger, W.: Chancen nutzen, Verantwortung übernehmen. Aufgaben für Politik, Industrie und Gesellschaft. In: Pharmastandort Deutschland-Eine Standortbestimmung. Verband Forschender Arzneimittelhersteller 1994.
205. Wiggins, S.N.: The cost of developing a new drug. Pharmaceutical Manufacturer Association, Washington, DC, June 1987.
206. Winck, P.: Pharma-Projektmanagement (PPM). Die Pharm. Industrie 49: 911-915, 1987.
207. Wofford, J.C.: A cognitive interpretation of transactional and transformational leadership theories. Leadership Quarterly 5:161-186,1994.
208. Wolters, H.-G.: Tierversuche auf dem Prüfstand von Öffentlichkeit und Politik. Tierversuch-Experten sagen ihre Meinung. Hrsg. Abteilung für Öffentlichkeitsarbeit der Hoechst AG, Bäumler, E. and Fricke, J. (eds.).
209. Wood, D.: The battle for survival-do branded drugs have a future? Scrip Magazine 11:10,1994.
210. Wright, R.A.: Human values in health care. The practise of ethics. McGraw-Hill, New York, 1987.
211. Zbinden, G.: In: National and International Drug Safety Guidelines. S. Adler & G. Zbinden (eds.), Zollikon: MTC Verlag, 7-19,1988.
212. Zechendorfer, B.: What the public thinks about biotechnology. Bio/Technol. 12, 1994.